Chong Chyn Chua1,2, Andrew W Roberts3,4,5, John Reynolds6, Chun Yew Fong7, Stephen B Ting8, Jessica M Salmon2, Sarah MacRaild1,2, Adam Ivey1, Ing Soo Tiong1,2, Shaun Fleming1,2, Fiona C Brown2, Sun Loo1, Ian J Majewski3,4, Stefan K Bohlander1, Andrew H Wei1,2. 1. Department of Haematology, The Alfred Hospital, Melbourne, Victoria, Australia. 2. Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia. 3. Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia. 4. Department of Medical Biology, University of Melbourne, Melbourne, Australia. 5. Department of Haematology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia. 6. The Alfred and Faculty of Medicine, Nursing and Health Sciences, Monash University, Victoria, Australia. 7. Department of Haematology, Austin Hospital, Heidelberg, Victoria, Australia. 8. Department of Haematology, Box Hill Hospital, Box Hill, Victoria, Australia.
Abstract
PURPOSE: The B-cell lymphoma 2 (BCL-2) inhibitor venetoclax has an emerging role in acute myeloid leukemia (AML), with promising response rates in combination with hypomethylating agents or low-dose cytarabine in older patients. The tolerability and efficacy of venetoclax in combination with intensive chemotherapy in AML is unknown. PATIENTS AND METHODS: Patients with AML who were ≥ 65 years (≥ 60 years if monosomal karyotype) and fit for intensive chemotherapy were allocated to venetoclax dose-escalation cohorts (range, 50-600 mg). Venetoclax was administered orally for 14 days each cycle. During induction, a 7-day prephase/dose ramp-up (days -6 to 0) was followed by an additional 7 days of venetoclax combined with infusional cytarabine 100 mg/m2 on days 1-5 and idarubicin 12 mg/m2 intravenously on days 2-3 (ie, 5 + 2). Consolidation (4 cycles) included 14 days of venetoclax (days -6 to 7) combined with cytarabine (days 1-2) and idarubicin (day 1). Maintenance venetoclax was permitted (7 cycles). The primary objective was to assess the optimal dose schedule of venetoclax with 5 + 2. RESULTS: Fifty-one patients with a median age of 72 years (range, 63-80 years) were included. The maximum tolerated dose was not reached with venetoclax 600 mg/day. The main grade ≥ 3 nonhematologic toxicities during induction were febrile neutropenia (55%) and sepsis (35%). In contrast to induction, platelet recovery was notably delayed during consolidation cycles. The overall response rate (complete remission [CR]/CR with incomplete count recovery) was 72%; it was 97% in de novo AML and was 43% in secondary AML. During the venetoclax prephase, marrow blast reductions (≥ 50%) were noted in NPM1-, IDH2-, and SRSF2-mutant AML. CONCLUSION: Venetoclax combined with 5 + 2 induction chemotherapy was safe and tolerable in fit older patients with AML. Although the optimal postremission therapy remains to be determined, the high remission rate in de novo AML warrants additional investigation (ANZ Clinical Trial Registry No. ACTRN12616000445471).
PURPOSE: The B-cell lymphoma 2 (BCL-2) inhibitor venetoclax has an emerging role in acute myeloid leukemia (AML), with promising response rates in combination with hypomethylating agents or low-dose cytarabine in older patients. The tolerability and efficacy of venetoclax in combination with intensive chemotherapy in AML is unknown. PATIENTS AND METHODS: Patients with AML who were ≥ 65 years (≥ 60 years if monosomal karyotype) and fit for intensive chemotherapy were allocated to venetoclax dose-escalation cohorts (range, 50-600 mg). Venetoclax was administered orally for 14 days each cycle. During induction, a 7-day prephase/dose ramp-up (days -6 to 0) was followed by an additional 7 days of venetoclax combined with infusional cytarabine 100 mg/m2 on days 1-5 and idarubicin 12 mg/m2 intravenously on days 2-3 (ie, 5 + 2). Consolidation (4 cycles) included 14 days of venetoclax (days -6 to 7) combined with cytarabine (days 1-2) and idarubicin (day 1). Maintenance venetoclax was permitted (7 cycles). The primary objective was to assess the optimal dose schedule of venetoclax with 5 + 2. RESULTS: Fifty-one patients with a median age of 72 years (range, 63-80 years) were included. The maximum tolerated dose was not reached with venetoclax 600 mg/day. The main grade ≥ 3 nonhematologic toxicities during induction were febrile neutropenia (55%) and sepsis (35%). In contrast to induction, platelet recovery was notably delayed during consolidation cycles. The overall response rate (complete remission [CR]/CR with incomplete count recovery) was 72%; it was 97% in de novo AML and was 43% in secondary AML. During the venetoclax prephase, marrow blast reductions (≥ 50%) were noted in NPM1-, IDH2-, and SRSF2-mutant AML. CONCLUSION: Venetoclax combined with 5 + 2 induction chemotherapy was safe and tolerable in fit older patients with AML. Although the optimal postremission therapy remains to be determined, the high remission rate in de novo AML warrants additional investigation (ANZ Clinical Trial Registry No. ACTRN12616000445471).
Authors: Sarah T Diepstraten; Mary Ann Anderson; Peter E Czabotar; Guillaume Lessene; Andreas Strasser; Gemma L Kelly Journal: Nat Rev Cancer Date: 2021-10-18 Impact factor: 60.716
Authors: Hagop M Kantarjian; Nitin Jain; Guillermo Garcia-Manero; Mary Alma Welch; Farhad Ravandi; William G Wierda; Elias J Jabbour Journal: Cancer Date: 2021-10-06 Impact factor: 6.860
Authors: Hagop Kantarjian; Nicholas J Short; Courtney DiNardo; Eytan M Stein; Naval Daver; Alexander E Perl; Eunice S Wang; Andrew Wei; Martin Tallman Journal: Lancet Haematol Date: 2021-10-20 Impact factor: 18.959
Authors: Ashley M Nelson; Hermioni L Amonoo; Alison R Kavanaugh; Jason A Webb; Vicki A Jackson; Julia Rice; Mitchell W Lavoie; Amir T Fathi; Andrew M Brunner; Joseph A Greer; Jennifer S Temel; Areej El-Jawahri; Thomas W LeBlanc Journal: Cancer Date: 2021-08-30 Impact factor: 6.921
Authors: Curtis A Lachowiez; Sanam Loghavi; Ken Furudate; Guillermo Montalban-Bravo; Abhishek Maiti; Tapan Kadia; Naval Daver; Gautam Borthakur; Naveen Pemmaraju; Koji Sasaki; Yesid Alvarado; Musa Yilmaz; Nicholas J Short; Kelly Chien; Maro Ohanian; Sherry Pierce; Keyur P Patel; Elias Jabbour; Farhad Ravandi; Hagop M Kantarjian; Guillermo Garcia-Manero; Koichi Takahashi; Marina Y Konopleva; Courtney D DiNardo Journal: Blood Adv Date: 2021-04-27
Authors: Rachel Thijssen; Sarah T Diepstraten; Donia Moujalled; Edward Chew; Christoffer Flensburg; Melissa X Shi; Michael A Dengler; Veronique Litalien; Sarah MacRaild; Maoshan Chen; Natasha S Anstee; Boris Reljić; Sarah S Gabriel; Tirta M Djajawi; Chris D Riffkin; Brandon J Aubrey; Catherine Chang; Lin Tai; Zhen Xu; Thomas Morley; Giovanna Pomilio; Claudia Bruedigam; Axel Kallies; David A Stroud; Ashish Bajel; Ruth M Kluck; Steven W Lane; Marie Schoumacher; Sébastien Banquet; Ian J Majewski; Andreas Strasser; Andrew W Roberts; David C S Huang; Fiona C Brown; Gemma L Kelly; Andrew H Wei Journal: Blood Date: 2021-05-20 Impact factor: 22.113
Authors: Tapan M Kadia; Patrick K Reville; Gautam Borthakur; Musa Yilmaz; Steven Kornblau; Yesid Alvarado; Courtney D Dinardo; Naval Daver; Nitin Jain; Naveen Pemmaraju; Nicholas Short; Sa A Wang; Rebecca S S Tidwell; Rabiul Islam; Marina Konopleva; Guillermo Garcia-Manero; Farhad Ravandi; Hagop M Kantarjian Journal: Lancet Haematol Date: 2021-08 Impact factor: 30.153